<?xml version="1.0" encoding="UTF-8"?>
<p id="Par13">Also, due to the role of dendritic cells in the immune response and its highly susceptibility to ZIKV infection we decide to test the antiviral activity of NAR in human monocyte-derived dendritic cells (hmdDCs)
 <sup>
  <xref ref-type="bibr" rid="CR41">41</xref>–
  <xref ref-type="bibr" rid="CR43">43</xref>
 </sup>. First, it was shown that the concentration of 125 µM of NAR was not toxic to hmdDCs and would be used as the MNTC (Fig. 
 <xref rid="Fig7" ref-type="fig">7B</xref>). Next, it was demonstrated that NAR (125 µM) effectively reduced the number of ZIKV-infected hmdDCs as well as the viral titers in cell culture supernatants (Fig. 
 <xref rid="Fig7" ref-type="fig">7C–E</xref>). Altogether, the results demonstrated that NAR is able to impair the infection of hmdDCs, a key target cell for ZIKV infection and for the immune system function
 <sup>
  <xref ref-type="bibr" rid="CR41">41</xref>,
  <xref ref-type="bibr" rid="CR44">44</xref>
 </sup>.
</p>
